|Day Low/High||4.14 / 4.30|
|52 Wk Low/High||3.24 / 13.50|
CHA Bio Will Conduct and Fund the Trial; PLX-PAD Cells Are the First Placental-Derived Allogeneic Cells Approved for Importation Into South Korea
Important Milestone Advances Pluristem's Clinical Development Program for the Treatment of Preeclampsia Using PLX-PAD Cells
International Study Extends FDA Phase II Trial That Began in U.S.
Exclusive Rights to Treat PAD With Placental Cells in the U.S.
Pre-Clinical Studies Conducted at New York's Hospital for Special Surgery
Supports Expanding Product Portfolio in Both Clinical Trials and Pre-Clinical R&D
Positive Data From the First Study Prompts Decision
Study Conducted in Germany Marks the First Time PLX-PAD Cells are Used for the Treatment of Surgically Induced Muscle Trauma
Cha Will Conduct and Fund Multiple Peripheral Artery Disease Clinical Trials and Invest $10 Million Valued at $4/Share Into Pluristem Via a Share Exchange Agreement
Pluristem's Cells Were Reported to Serve as Highly Effective "Off the Shelf" Therapy to Treat Acute Radiation Syndrome and Radiation Induced Bone Marrow Failure in Animals
New Opportunities Discussed to Strengthen Collaborative Relationships Using Pluristem's Placental Expanded (PLX) Cells
No Treatment Exists Today for the Most Common Medical Complication of Pregnancy
Enhancing Hematopoietic Stem Cell Engraftment Will be the First Indication
Findings Presented at ISHLT Meeting in Montreal
Pluristem Plans to Initiate a Phase I Trial in Rotator Cuff Injuries
First Time Surgically Induced Muscle Injury Treated With PLX Cells
PLX Cells to be Administered Intravenously to Humans for the First Time, Opening Potential New Fields of Applications
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.